Evidence map›Paper›PMID 40098750›Full record

ArticleMolecular imaging

Effect of the TAAR1 Partial Agonist Ralmitaront on Presynaptic Dopamine Synthesis Capacity Measured Using [

David R Bonsall, Michelle Kokkinou, Els F Halff, Grazia Rutigliano, Sac-Pham Tang, Mattia Veronese, Elaine E Irvine, Dominic J Withers, Lisa A Wells, Sridhar Natesan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David R BonsallPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.
Michelle KokkinouPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.
Els F HalffPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.ORCID 0000-0001-5814-0899
Grazia RutiglianoPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.
Sac-Pham TangInvicro, Burlington Danes, Hammersmith Hospital, London, UK.
Mattia VeroneseDepartment of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID 0000-0003-3562-0683
Elaine E IrvineInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Dominic J WithersInstitute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK.
Lisa A WellsInvicro, Burlington Danes, Hammersmith Hospital, London, UK.
Sridhar NatesanPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.ORCID 0000-0001-7499-1714
Irene GerlachRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.
Štefan HoligaRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.
Marius C HoenerRoche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.
Oliver D HowesPsychiatric Imaging Group, MRC Laboratory of Medical Sciences (LMS), London, UK.

Funding

Medical Research Council (MRC) 094849/Z/10/ZMedical Research Council (MRC) MC-A654-5QB40Medical Research Council (MRC) MC_A656_5QD30_2135Wellcome Trust Digital Award 215747/Z/19/Z
6 · The paper itself

Abstract

Purpose: Elevated dopamine synthesis capacity is part of the pathophysiology of schizophrenia thought to underlie psychosis. Drugs that reduce this phenomenon could thus be potential treatments for these disorders. In this study, we evaluated the ability of the trace amine-associated receptor 1 (TAAR1) partial agonist ralmitaront to reduce presynaptic dopamine synthesis capacity. Procedures: Ralmitaront (3 mg/kg, i.p.), a TAAR1 partial agonist, was evaluated using [ Results: Cocaine treatment on its own did not induce elevated dopamine synthesis capacity when compared to the control group. Pretreatment with ralmitaront significantly reduced dopamine synthesis capacity when given either alone (44%) or in combination with the psychostimulant cocaine (50%) when compared to the control group. Conclusions: The TAAR1 agonist ralmitaront reduces striatal dopamine synthesis capacity, indexed as Ki

Indexed as

CocaineDihydroxyphenylalanineDopaminePositron-Emission TomographyPresynaptic TerminalsReceptors, G-Protein-CoupledAnimalsMaleMiceMice, Inbred C57BLTrace Amine-Associated ReceptorsCocaineDihydroxyphenylalanineDopaminefluorodopa F 18Receptors, G-Protein-CoupledTrace Amine-Associated ReceptorscocainedopaminePET imagingschizophreniaTAAR1 agonist

Identifiers

PMID40098750
PMCPMC11911367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.